Sanctions for Selective Endpoint Switching in Trial Reports

Introduction

Selective endpoint switching refers to changing, replacing, or selectively reporting clinical-trial endpoints after a study has begun, particularly when the original endpoint produces unfavourable or statistically insignificant results. An endpoint is a predefined measure used to assess the effect of a treatment, such as survival, symptom improvement, disease progression, or adverse events.

Endpoint switching is not automatically unlawful. A change may be scientifically justified because of new evidence, safety concerns, or methodological problems. However, changing an endpoint without proper justification, concealing the original plan, or presenting an exploratory outcome as though it were prespecified may mislead regulators, researchers, investors, and patients.

In biotechnology and pharmaceutical research, such conduct can undermine scientific integrity and create regulatory, civil, or criminal liability. The legal consequences depend on whether the conduct violates clinical-trial rules, reporting requirements, research-integrity standards, securities laws, or prohibitions against fraud.

Case Laws and Enforcement Examples

1. Frater v. Hemispherx Biopharma, Inc., 2013

In this U.S. securities litigation, investors alleged that clinical trials of Ampligen departed from their prespecified design, including changes to trial duration, endpoints, and statistical analysis. The case illustrates how alleged manipulation or selective presentation of trial results may become relevant to securities-fraud claims when allegedly misleading statements are made to investors. It is not a final judicial finding that endpoint switching itself constitutes fraud; the allegations and procedural context must be distinguished from a proven violation.

Justia Dockets & Filings

2. Seife v. FDA, 2018

This U.S. litigation concerning FDA approval of Exondys 51 raised concerns about changes to primary endpoints during the drug’s clinical development. The case materials discuss the scientific risk that post hoc endpoint selection can create false-positive findings. It illustrates why regulators scrutinise endpoint changes, although the discussion does not establish a universal rule that every endpoint revision is unlawful.

cornell1a.law.cornell.edu

3. FDA clinical-trial reporting enforcement

The FDA may issue a Notice of Noncompliance when a responsible party fails to register an applicable trial, submit required results, or knowingly submits false or misleading information. If the violation is not corrected, further enforcement may include civil money penalties, injunctions, or criminal prosecution. These are statutory enforcement mechanisms, not case-law precedents, but they demonstrate that inaccurate trial reporting can have direct legal consequences.

FDA

Indian Legal Framework

Under India’s New Drugs and Clinical Trials Rules, 2019, clinical trials must be conducted according to the approved protocol and Good Clinical Practices. If an amendment becomes necessary, its rationale must be provided through a protocol amendment. Results must be analysed according to the plan specified in the protocol.

IndiaCode+1

Accordingly, selectively replacing a failed primary endpoint with a favourable secondary endpoint, without transparent disclosure or proper amendment, may lead to:

Regulatory scrutiny or rejection of trial results.

Suspension or cancellation of clinical-trial permission where statutory grounds exist.

Investigation of the sponsor, investigator, or research institution.

Civil or securities-law liability if misleading statements cause legally recognised harm.

Potential criminal liability if the conduct satisfies the elements of an applicable offence, such as deliberate fraud or false reporting.

A scientifically justified endpoint revision should be documented, made before access to unblinded trial results where possible, and transparently reported. FDA guidance similarly warns that exchanging primary and secondary endpoints because the original endpoint appears unlikely to succeed can compromise scientific validity.

FDA

Conclusion

Sanctions for selective endpoint switching are designed to protect scientific integrity, patient safety, and the reliability of clinical-trial evidence. Endpoint changes are not automatically unlawful; their acceptability depends on scientific justification, timing, independence from trial results, regulatory approval where required, and transparent reporting.

The Indian NDCT Rules, 2019 require protocol adherence and analysis according to the specified plan. The cases Frater v. Hemispherx Biopharma and Seife v. FDA illustrate how endpoint changes may raise concerns about scientific validity and investor-facing statements, but they should not be treated as establishing that every endpoint change constitutes fraud. Ultimately, sanctions depend on the applicable law, the nature of the deviation, whether it was concealed or misleading, and the evidence of harm or regulatory non-compliance.